


PV-1019

Cat. No.:	HY-125203
CAS No.:	1093793-05-5
Molecular Formula:	C ₁₈ H ₁₇ N ₇ O ₃
Molecular Weight:	379.37
Target:	Checkpoint Kinase (Chk)
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PV-1019 (NSC 744039) is a potent, selective Chk2 inhibitor with an IC ₅₀ value of 24 nM. PV-1019 inhibits the Topotecan (HY-13768)-induced Chk2 autophosphorylation. PV-1019 inhibits IR-induced apoptosis ^[1] .																		
IC₅₀ & Target	Chk2 24 nM (IC ₅₀)																		
In Vitro	<p>PV-1019 (NSC 744039; 0.1-100 μM; 48 h) has antiproliferative effect in human tumor cells^[1].</p> <p>PV-1019 inhibits Chk2 autophosphorylation and histone H1 phosphorylation with an IC₅₀ value of 138 nM^[1].</p> <p>PV-1019 (1-50 μM; 1 h; OVCAR-5 cells) inhibits the Topotecan-induced Chk2 autophosphorylation with an IC₅₀ value of 2.8 μM^[1].</p> <p>PV-1019 (1 μM; 16 h) abrogates IR-induced apoptosis in mouse thymocytes^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>human tumor cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell growth in a dose-dependent manner.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>OVCAR-5 cells</td> </tr> <tr> <td>Concentration:</td> <td>1, 5, 10, and 25 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased the level of Chk2 autophosphorylation (Ser516) in a dose-dependent manner.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>mouse thymocytes</td> </tr> </table>	Cell Line:	human tumor cells	Concentration:	0.1-100 μM	Incubation Time:	48 hours	Result:	Inhibited cell growth in a dose-dependent manner.	Cell Line:	OVCAR-5 cells	Concentration:	1, 5, 10, and 25 μM	Incubation Time:	1 hours	Result:	Decreased the level of Chk2 autophosphorylation (Ser516) in a dose-dependent manner.	Cell Line:	mouse thymocytes
Cell Line:	human tumor cells																		
Concentration:	0.1-100 μM																		
Incubation Time:	48 hours																		
Result:	Inhibited cell growth in a dose-dependent manner.																		
Cell Line:	OVCAR-5 cells																		
Concentration:	1, 5, 10, and 25 μM																		
Incubation Time:	1 hours																		
Result:	Decreased the level of Chk2 autophosphorylation (Ser516) in a dose-dependent manner.																		
Cell Line:	mouse thymocytes																		

Concentration:	1 μ M
Incubation Time:	16 hours
Result:	Decreased in the sub-G1 fraction (56%).

REFERENCES

[1]. Jobson AG, et, al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazono)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA